nDatalyze 관리

관리 기준 확인 3/4

nDatalyze CEO는 James Durward, Jan2018 에 임명되었습니다 의 임기는 6.83 년입니다. 는 CA$ 805.28K 가치에 해당하는 회사 주식의 19.98% 직접 소유합니다. 805.28K. 경영진과 이사회의 평균 재임 기간은 각각 5.6 년과 6.7 년입니다.

주요 정보

James Durward

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	6.8yrs
CEO 소유권	20.0%
경영진 평균 재임 기간	5.6yrs
이사회 평균 재임 기간	6.7yrs

최근 관리 업데이트

Recent updates

Is MedXtractor Corp.'s (CSE:MXT) 1.1% ROE Worse Than Average?

Jan 14

CEO 보상 분석

James Durward 의 보수는 nDatalyze 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Aug 31 2024	n/a	n/a	-CA$668k
May 31 2024	n/a	n/a	-CA$310k
Feb 29 2024	n/a	n/a	-CA$156k
Nov 30 2023	n/a	n/a	-CA$550k
Aug 31 2023	n/a	n/a	-CA$612k
May 31 2023	n/a	n/a	-CA$1m
Feb 28 2023	CA$27k	CA$27k	-CA$1m
Nov 30 2022	n/a	n/a	-CA$2m
Aug 31 2022	n/a	n/a	-CA$2m
May 31 2022	n/a	n/a	-CA$1m
Feb 28 2022	n/a	n/a	-CA$1m
Nov 30 2021	n/a	n/a	-CA$918k
Aug 31 2021	n/a	n/a	-CA$895k
May 31 2021	n/a	n/a	-CA$785k
Feb 28 2021	CA$184k	CA$5k	-CA$699k
Nov 30 2020	n/a	n/a	CA$7k
Aug 31 2020	n/a	n/a	CA$39k
May 31 2020	n/a	n/a	-CA$2k
Feb 29 2020	CA$43k	CA$25k	-CA$37k
Nov 30 2019	n/a	n/a	-CA$47k
Aug 31 2019	n/a	n/a	-CA$100k
May 31 2019	n/a	n/a	-CA$82k
Feb 28 2019	CA$87k	CA$25k	-CA$237k

보상 대 시장: Canadian 시장에서 비슷한 규모의 회사에 비해 James 의 총 보상이 합리적인지 여부를 입증하기에는 데이터가 부족합니다.

보상과 수익: James 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

James Durward (69 yo)

6.8yrs

테뉴어

CA$26,500

보상

Mr. James Morris Durward serves as Chief Executive Officer, Corporate Secretary and Director at nDatalyze Corp. (formerly known as MedXtractor Corp.) since January 24, 2018 and served as its President unti...

리더십 팀

이름	위치	테뉴어	보상	소유권
James Durward	Chief Technical Officer	6.8yrs	CA$26.50k	19.98% CA$ 805.3k
Dwayne Vinck	Chief Financial Officer	5.6yrs	CA$21.69k	1.96% CA$ 79.1k
Keith Courtney	Chief Psychiatric Officer	less than a year	데이터 없음	데이터 없음

5.6yrs

평균 재임 기간

경험이 풍부한 관리: NDAT 의 관리팀은 노련하고 경험 (평균 재직 기간 5.6 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
James Durward	Chief Technical Officer	6.8yrs	CA$26.50k	19.98% CA$ 805.3k
G. Price	Independent Director	6.8yrs	데이터 없음	2.71% CA$ 109.3k
Dusan Kuzma	Independent Director	6.7yrs	데이터 없음	0.50% CA$ 20.1k
Gordon Crawford	Independent Director	4yrs	데이터 없음	2.59% CA$ 104.5k

6.7yrs

평균 재임 기간

69yo

평균 연령

경험이 풍부한 이사회: NDAT 의 이사회는 경험(평균 재직 기간 6.7 년)으로 간주됩니다.

nDatalyze 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

nDatalyze Corp. Announces Change in President

Ndatalyze Corp. Announces Executive Changes

nDatalyze Corp., Annual General Meeting, Mar 14, 2024

Insufficient new directors

nDatalyze Corp. Announces Appointment of Dr. Keith Courtney as President and Chief Psychiatric Officer

nDatalyze Corp., Annual General Meeting, Nov 30, 2022

Recent updates

Second quarter 2025 earnings released: CA$0.005 loss per share (vs CA$0.004 profit in 2Q 2024)

nDatalyze Corp. Announces Positive Clinical Study Results, and Mindbalanced Update

New minor risk - Share price stability

nDatalyze Corp. Announces Change in President

Full year 2024 earnings released: CA$0.004 loss per share (vs CA$0.032 loss in FY 2023)

nDatalyze Corp. Announces Clinical Study Update

nDatalyze Corp. Updates the Clinical Study

nDatalyze Corp. announced that it has received CAD 0.20625 million in funding

nDatalyze Corp. announced that it expects to receive CAD 0.20625 million in funding

Ndatalyze Corp. Announces Executive Changes

nDatalyze Corp. (CNSX:NDAT) completed the acquisition of Mindbalanced Inc.

New minor risk - Share price stability

nDatalyze Corp., Annual General Meeting, Mar 14, 2024

Third quarter 2024 earnings released: CA$0.004 loss per share (vs CA$0.006 loss in 3Q 2023)

Insufficient new directors

New minor risk - Shareholder dilution

nDatalyze Corp. announced that it has received CAD 0.2778 million in funding

nDatalyze Corp. Announces Appointment of Dr. Keith Courtney as President and Chief Psychiatric Officer

Second quarter 2024 earnings released: EPS: CA$0.004 (vs CA$0.006 loss in 2Q 2023)

nDatalyze Corp. Advances Its Clinical Study Process

nDatalyze Corp. Begins a Clinical Study Process

nDatalyze Corp. Begins a Clinical Study Process

Full year 2023 earnings released: CA$0.032 loss per share (vs CA$0.032 loss in FY 2022)

Third quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.001 loss in 3Q 2022)

nDatalyze Corp. Anticipates YMI ChatGPT Testing

nDatalyze Corp. Announces Two Video Initiatives to Augment Its Phase 2 Marketing Program

nDatalyze Corp. Announces Canada-Wide Release of YMI

Second quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.003 loss in 2Q 2022)

nDatalyze Corp., Annual General Meeting, Nov 30, 2022

First quarter 2023 earnings released: CA$0.007 loss per share (vs CA$0.002 loss in 1Q 2022)

Full year 2022 earnings released: CA$0.032 loss per share (vs CA$0.027 loss in FY 2021)

nDatalyze Announces YMI mHealth Application Beta is Now Online

nDatalyze Corp. announced that it expects to receive CAD 1.25 million in funding

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

nDatalyze Announces Successful Proof-Of-Concept and Progress Update

Second quarter 2022 earnings released: CA$0.003 loss per share (vs CA$0.001 profit in 2Q 2021)

First quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.001 profit in 1Q 2021)

Medxtractor Corp Updates Reference Record Collection Progress

Full year 2021 earnings released: CA$0.027 loss per share (vs CA$0.002 loss in FY 2020)

MedXtractor Corp. announced that it has received CAD 1.815 million in funding

President exercised options and sold CA$78k worth of stock

Chief Financial Officer recently sold CA$99k worth of stock

New 90-day high: CA$0.27

MedXtractor Corp. announced that it expects to receive CAD 1.6 million in funding

Medxtractor Corp. Updates the SHAMAN Psychedelics Artificial Intelligence Project

New 90-day high: CA$0.24

New 90-day high: CA$0.21

Is MedXtractor Corp.'s (CSE:MXT) 1.1% ROE Worse Than Average?

Medxtractor Corp. Announces Commencement of "SHAMAN"

Third quarter 2021 earnings released: CA$0.001 loss per share

MedXtractor Corp. Announces Board Changes

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간

평균 연령